The January 2027 unblinding and FDA meeting request are the next key catalysts. Watch for expanded access data in early November 2026, which could provide an early signal on tafenoquine's efficacy in treatment-refractory babesiosis. The stock has shown high sensitivity to pipeline news historically — binary outcome risk is elevated.
Price Chart
Executive Summary
60 Degrees Pharmaceuticals announced it will conclude enrollment in its Phase 2 severe babesiosis study at 30 patients (vs. planned 33) after a DSMB interim analysis found no safety issues and recommended completing the original plan. The company will unblind and report primary/secondary endpoint results in January 2027, and plans to request a pre-sNDA meeting with the FDA that same month to discuss a potential accelerated approval pathway for tafenoquine in babesiosis, supported by published case reports and expanded access data. This is a binary catalyst event with results expected in ~3 months, but the stock has historically moved sharply on prior reports.
Key Facts
- DSMB interim analysis recommended completing the originally planned enrollment of 33 patients; no safety issues identified.
- Company concluded enrollment at 30 patients due to marginal statistical power gain from 3 additional subjects and seasonal enrollment delays.
- Primary and secondary endpoint results expected in January 2027.
- Company will request a pre-sNDA meeting with FDA in January 2027 to discuss data requirements and potential accelerated approval pathway.
- Expanded access study showed molecular cure in first 3 patients; final screening data from 2 more patients expected early November 2026.
- No FDA-approved treatment exists for human babesiosis; tafenoquine is currently approved only for malaria prevention.
- Study is double-blind, randomized, placebo-controlled, multi-site (NCT06207370) evaluating tafenoquine + standard of care vs. placebo + standard of care in severe babesiosis.
Financial Impact
Binary catalyst — positive results could open a new FDA-approved indication for tafenoquine in an orphan-like disease with no approved therapy; negative results would significantly impair the babesiosis development program. No financial figures stated in the release.
Risk Factors
- Study may fail to meet primary or secondary endpoints, eliminating the severe babesiosis approval path.
- FDA may not accept a case-report-only data package or NAT-based surrogate endpoint for accelerated approval.
- Seasonal babesiosis enrollment delays could push unblinding beyond January 2027 if additional patients were needed.
- Going-concern risk noted in forward-looking statements — company may lack resources to fund further development without positive results or financing.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3375462 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $0.8759 | awaiting T+5 | — | $0.8700 (−0.67%) |
Oct 6, 2026 20d ago | Press Release | $1.11 $0.9000 | ▼ −18.92% | ▼ −18.78% | $0.8700 (−21.62%) |
Oct 6, 2026 20d ago | 8-K | $1.11 $0.9000 | ▼ −18.92% | ▼ −18.78% | $0.8700 (−21.62%) |
Aug 26, 2026 8w ago | EFFECT | $1.08 $0.9495 | ▲ +12.08% | ▲ +11.96% | $0.8700 (+19.44%) |
Aug 14, 2026 10w ago | Press Release | $1.20 $1.13 | ▲ +5.44% | ▲ +4.07% | $0.8700 (+27.20%) |
Jul 30, 2026 12w ago | Press Release | $1.25 $1.15 | ▲ +8.00% | ▲ +11.62% | $0.8700 (+30.40%) |
Jul 1, 2026 16w ago | Press Release | $1.75 $1.55 | ▼ −11.43% | ▼ −11.38% | $0.8700 (−50.29%) |
May 26, 2026 21w ago | Press Release | $1.50 $1.46 | ▼ −2.67% | ▼ −3.75% | $0.8700 (−42.00%) |
May 15, 2026 23w ago | Press Release | $1.39 $1.48 | ▼ −6.47% | ▼ −5.51% | $0.8700 (+37.41%) |
Mar 31, 2026 29w ago | Press Release | $1.75 $1.81 | ▲ +3.43% | ▼ −0.52% | $0.8700 (−50.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers